Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls

Sims, Travis T.; Colbert, Lauren E.; Zheng, Jiali; Medrano, Andrea Y. Delgado; Hoffman, Kristi L.; Ramondetta, Lois M.; Jazaeri, Amir A.; Jhingran, Anuja; Schmeler, Kathleen M.; Daniel, Carrie R.; Klopp, Ann H.

doi:10.1016/j.ygyno.2019.09.002

Cited by 60 publications

(52 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[50] In a larger analysis of the gut microbiome in cervical cancer patients versus women without cervical cancer, our group observed a statistically significant higher a-diversity in cervical cancer patients than in healthy controls. [51] We also observed a statistically significant difference in b-diversity between women with cervical cancer and women without cervical cancer, confirming compositional differences in the gut microbiota between these two groups. Our ongoing studies suggest that both the cervical and gut microbiomes are associated with treatment response and outcomes in cervical cancers.…”

Section: Gut Microbiome Factors In Invasive Cervical Cancersupporting

confidence: 75%

The Role of the Cervicovaginal and Gut Microbiome in Cervical Intraepithelial Neoplasia and Cervical Cancer

Sims

Colbert

Klopp

2020

Journal of Immunotherapy and Precision Oncology

Self Cite

View full text Add to dashboard Cite

The microbiome, which refers to the microbiota within a host and their collective genomes, has recently been demonstrated to play a critical role in cancer progression, metastasis, and therapeutic response. The microbiome is known to affect host immunity, but its influence on human papilloma virus (HPV) gynecologic malignancies remains limited and poorly understood. To date, studies have largely focused on the cervicovaginal microbiome; however, there is growing evidence that the gut microbiome may interact and substantially affect therapeutic response in gynecologic cancers. Importantly, new developments in microbiome sequencing and advanced bioinformatics technologies have enabled rapid advances in our understanding of the gut and local tumor microbiota. In this review, we examine the evidence supporting the role of the microbiome in HPV-associated cervical intraepithelial neoplasia (CIN) and cervical cancer, explore characteristics that influence and shape the host microbiota that impact HPV-driven carcinogenesis, and highlight potential approaches and considerations for future and ongoing research of the microbiome's effect on HPV-associated cancer.

show abstract

Section: Gut Microbiome Factors In Invasive Cervical Cancersupporting

confidence: 75%

The Role of the Cervicovaginal and Gut Microbiome in Cervical Intraepithelial Neoplasia and Cervical Cancer

Sims

Colbert

Klopp

2020

Journal of Immunotherapy and Precision Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although a rule of thumb is that cancer risk is inversely linked to high microbial diversity [ 73 ], there are exceptions to this rule. For example, the microbial diversity is reported to be significantly higher in postmenopausal breast cancer patients than in postmenopausal controls [ 74 ], or in cervical cancer patients than in healthy controls [ 75 ].…”

Section: Discussionmentioning

confidence: 99%

Genistein Reduces the Risk of Local Mammary Cancer Recurrence and Ameliorates Alterations in the Gut Microbiota in the Offspring of Obese Dams

et al. 2021

View full text Add to dashboard Cite

The risk of recurrence of estrogen receptor-positive breast cancer remains constant, even 20 years after diagnosis. Recurrence may be more likely in patients pre-programmed for it already in the womb, such as in the daughters born to obese mothers. Maternal obesity persistently alters offspring’s gut microbiota and impairs tumor immune responses. To investigate if the gut dysbiosis is linked to increased risk of mammary cancer recurrence in the offspring of obese rat dams, we fed adult offspring genistein which is known to have beneficial effects on the gut bacteria. However, the effects of genistein on breast cancer remain controversial. We found that genistein intake after tamoxifen response prevented the increased risk of local recurrence in the offspring of obese dams but had no effect on the control offspring. A significant increase in the abundance of inflammatory Prevotellaceae and Enterobacteriaceae, and a reduction in short-chain fatty acid producing Clostridiaceae was observed in the offspring of obese dams. Genistein supplementation reversed these changes as well as reversed increased gut metabolite N-acetylvaline levels which are linked to increased all-cause mortality. Genistein supplementation also reduced genotoxic tyramine levels, increased metabolites improving pro-resolving phase of inflammation, and reversed the elevated tumor mRNA expression of multiple immunosuppressive genes in the offspring of obese dams. If translatable to breast cancer patients, attempts to prevent breast cancer recurrences might need to focus on dietary modifications which beneficially modify the gut microbiota.

show abstract

“…Several attempts have been made to theorize the association between intestinal microbiota and ICC [ 4 , 5 , 6 , 7 ]. Sims et al [ 8 ] reported differences in fecal microbial composition between patients with ICC and healthy controls, indicating that their gut microbiota reflect etiologic or clinical differences by age. Wang et al [ 9 ] demonstrated Proteobacteria, Parabacteroides , Escherichia – Shigella , and Roseburia as possible biomarkers for ICC diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Dynamics of Fecal Microbiota with and without Invasive Cervical Cancer and Its Application in Early Diagnosis

Kang

Jung

Lee

et al. 2020

Cancers

View full text Add to dashboard Cite

The fecal microbiota is being increasingly implicated in the diagnosis of various diseases. However, evidence on changes in the fecal microbiota in invasive cervical cancer (ICC) remains scarce. Here, we aimed to investigate the fecal microbiota of our cohorts, develop a diagnostic model for predicting early ICC, and identify potential fecal microbiota-derived biomarkers using amplicon sequencing data. We obtained fecal samples from 29 healthy women (HC) and 17 women with clinically confirmed early ICC (CAN). Although Shannon’s diversity index was not reached at statistical significance, the Chao1 and Observed operational taxonomic units (OTUs) in fecal microbiota was significantly different between CAN and HC group. Furthermore, there were significant differences in the taxonomic profiles between HC and CAN; Prevotella was significantly more abundant in the CAN group and Clostridium in the HC group. Linear discriminant analysis effect size (LEfSe) analysis was applied to validate the taxonomic differences at the genus level. Furthermore, we identified a set of seven bacterial genera that were used to construct a machine learning (ML)-based classifier model to distinguish CAN from patients with HC. The model had high diagnostic utility (area under the curve [AUC] = 0.913) for predicting early ICC. Our study provides an initial step toward exploring the fecal microbiota and helps clinicians diagnose.

show abstract

Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls

Cited by 60 publications

References 38 publications

The Role of the Cervicovaginal and Gut Microbiome in Cervical Intraepithelial Neoplasia and Cervical Cancer

The Role of the Cervicovaginal and Gut Microbiome in Cervical Intraepithelial Neoplasia and Cervical Cancer

Genistein Reduces the Risk of Local Mammary Cancer Recurrence and Ameliorates Alterations in the Gut Microbiota in the Offspring of Obese Dams

Dynamics of Fecal Microbiota with and without Invasive Cervical Cancer and Its Application in Early Diagnosis

Contact Info

Product

Resources

About